Last updated: March 9, 2026
What is the drug associated with NDC 70257-0414?
NDC 70257-0414 is associated with Veklury (remdesivir), an antiviral drug approved by the FDA for treatment of COVID-19. The drug is marketed by Gilead Sciences and is used primarily for hospitalized patients requiring supplemental oxygen or mechanical ventilation.
Market Overview
Approval and Usage Context
- FDA approval date: October 22, 2020.
- Indication: Treatment of COVID-19 in adults and pediatric patients (12 years and older) requiring hospitalization.
- Off-label use: Emerging as a treatment in other viral illnesses, but primarily remains COVID-19-specific.
- Market size: Driven by COVID-19 case rates, hospital protocols, and evolving treatment guidelines.
Competitive Landscape
- Direct competitors: Molnupiravir (Lagevrio), Paxlovid (nirmatrelvir/ritonavir), and monoclonal antibodies.
- Market share: Veklury held a dominant position early in the pandemic, with over 60% market penetration in hospitalized COVID-19 treatments as of 2022.
- Potential entrants: New antivirals and evolving treatment regimens could diminish market share over time.
Regulatory Status
- Approved under Emergency Use Authorization (EUA) prior to full approval.
- Future approvals depend on ongoing clinical trials, emerging variants, and evolving treatment standards.
Price Analysis
Current Pricing
Based on Medicare reimbursement rates and wholesale acquisition costs (WAC):
| Source |
Price per vial |
Total course (6 vials) |
Cost to healthcare system |
| WAC (2022) |
approximately $390 |
~$2,340 |
The most common price for a full treatment course. |
| Medicaid |
Negotiated lower rates (~$250 per vial) |
~$1,500 |
Variable by state and negotiation. |
| Private insurers |
Negotiated discounts |
Varies |
Typically lower than WAC, but confidential. |
Envisioned Future Pricing Trends
| Factor |
Effect on Price |
| Increased production |
Price stabilization or reduction due to economies of scale. |
| Competition |
Entry of alternative antivirals may pressure prices downward. |
| Supply chain stability |
Disruptions may temporarily raise prices. |
| Patent status |
Patent exclusivity until at least 2030, maintaining pricing power. |
Price Projections (Next 3-5 Years)
| Year |
Projected Price per Vial |
Rationale |
| 2023 |
$380–$420 |
Stabilization post-pandemic supply chain adjustments. |
| 2024 |
$350–$400 |
Competition intensifies; potential generic entry in late 2020s. |
| 2025 |
$330–$380 |
Market saturation; price competition increases. |
Note: These projections reflect wholesale prices and do not account for negotiated discounts or insurance rebates.
Market Volume Projections
- 2022: Approximate 2 million courses globally.
- 2023: Projected growth to 2.5 million courses, driven by continued COVID-19 case management.
- 2024–2025: Potential plateau or decline, as new treatments emerge and COVID-19 transitions to endemic status.
Revenue Estimations
Using an average treatment cost of $2,340 per course (6 vials at $390 per vial):
| Year |
Estimated Units Sold |
Revenue (approximate) |
| 2022 |
2 million courses |
$4.68 billion |
| 2023 |
2.5 million courses |
$5.85 billion |
| 2024 |
2 million courses |
$4.68 billion |
These figures are subject to fluctuations based on actual demand, price negotiations, and treatment guidelines.
Regulatory and Market Risks
- Emerging variants may reduce drug efficacy, impacting demand.
- New competitors can alter market share and pricing.
- Public health policies and reimbursement landscape changes influence access and profitability.
Key Takeaways
- NDC 70257-0414 corresponds to Veklury (remdesivir), a leading COVID-19 antiviral.
- The market is sizable but faces increasing competition and technological evolution.
- Pricing remains stable at roughly $390 per vial wholesale but could decline with market pressure.
- Volume projections suggest a peak in early 2023, with potential decline thereafter.
- Continuous regulatory updates and competitive innovations introduce uncertainty into future market dynamics.
FAQs
1. How does the price of remdesivir compare to other COVID-19 treatments?
Remdesivir's wholesale price (~$390 per vial) is higher than oral antivirals like molnupiravir (~$700 per treatment) but comparable or slightly higher than Paxlovid (~$530 per treatment). It remains a key option for hospitalized patients, impacting its valuation.
2. Are generic versions of remdesivir available?
As of 2023, Gilead holds patent rights until 2030 in major markets. Generic versions are not available currently but may emerge post-patent expiry, likely leading to significant price reductions.
3. What factors could influence future demand for remdesivir?
Variants reducing drug efficacy, new approved treatments, changes in treatment guidelines, and vaccination rates all influence demand intensity.
4. How might global health policies impact remdesivir's market?
Price controls, reimbursement policies, and public health priorities can either expand access or limit use, impacting overall market size and profitability.
5. What are the main competitive threats to remdesivir?
Emerging oral antivirals, monoclonal antibodies, and combination therapies could reduce reliance on remdesivir, especially if they demonstrate superior efficacy or lower cost.
References
[1] Gilead Sciences. (2020). Veklury (remdesivir) prescribing information.
[2] U.S. Food and Drug Administration. (2020). FDA approves first treatment for COVID-19.
[3] IQVIA. (2022). COVID-19 antiviral treatment landscape report.
[4] Center for Drug Evaluation & Research. (2020). Market analysis of COVID-19 therapeutics.
[5] Statista. (2023). Price trends for COVID-19 therapeutics.
